Pacira Biosciences, Inc. - 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K was filed on October 15, 2015, by Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.). The report discloses a material change in executive leadership effective October 20, 2015.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
- Executive Appointment: James S. Scibetta was appointed President of the Company, effective October 20, 2015.
- Role Continuity: Mr. Scibetta will continue to serve as Chief Financial Officer (CFO) and Head of Technical Operations while a search for a new CFO is conducted. David Stack remains Chief Executive Officer and Chairman.
- Compensation Adjustment: In connection with the promotion, Mr. Scibetta's annual base salary was increased to $475,000.
- Incentive Plan: His annual incentive target was increased to 50% of his annual base salary for the pro rata portion of the 2015 fiscal year.
- Equity Grant: Mr. Scibetta received a grant of 40,000 stock options vesting over a four-year period.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. The only unusual item noted is the specific compensation adjustment tied to the executive promotion.
Key Facts for Investor Verification
- Confirmation of James S. Scibetta's dual role as President and interim CFO.
- Verification of the $475,000 base salary and 50% incentive target for Mr. Scibetta.
- Details regarding the vesting schedule of the 40,000 stock options granted.
- Timeline for the search and appointment of a permanent successor to the CFO role.